Intervention

Tecemotide (L-BLP25)

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

5 shown

Tecemotide (L-BLP25) in Prostate CancerNCT01496131 · 2011-10-24

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary ChemoradiotherapyNCT00960115 · 2008-12-01

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)NCT00409188 · 2007-01-01

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III DiseaseNCT00157196 · 2005-04-01

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)NCT00157209 · 2000-08-01

Common conditions

Carcinoma, Non-Small-Cell Lung2 Lung Neoplasms2 Non-small Cell Lung Cancer2 Prostate Cancer1

Leading sponsors

Merck KGaA, Darmstadt, Germany3 EMD Serono2

Trial status mix

COMPLETED5

Phase mix

PHASE24

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.